- Conditions
- No Condition
- Interventions
- chloroprocaine HCL 3%, Subconjunctival Lidocaine
- Drug
- Lead sponsor
- Retina Research Institute, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Glen Carbon, Illinois • Chesterfield, Missouri • City of Saint Peters, Missouri + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Geographic Atrophy
- Interventions
- Sirolimus, Lidocaine
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 55 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 13
- States / cities
- Loma Linda, California • Sacramento, California • Jacksonville, Florida + 10 more
- Conditions
- Blepharoptosis
- Interventions
- Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine, Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine
- Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
- Procedure · Drug
- Lead sponsor
- Retina Vitreous Associates of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Clearwater, Florida
- Conditions
- Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
- Interventions
- Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
- Drug · Procedure
- Lead sponsor
- Harrow Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Tyler, Texas
- Conditions
- Macular Degeneration
- Interventions
- Proparacaine Ophthalmic, Tetracaine Ophthalmic, Lidocaine 4%, Lidocaine 2% Injectable Solution
- Drug
- Lead sponsor
- Lahey Clinic
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- Arlington, Massachusetts • Burlington, Massachusetts • Peabody, Massachusetts